CSTL analyst estimates
Castle Biosciences (CSTL) analyst ratings, the average price target and its range, and every firm's latest call.
CSTL analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 3, 2026 | BTIG | Castle Biosciences (CSTL) PT Raised to $44 at BTIG | $44.00 |
| Jul 31, 2026 | Robert W. Baird | Castle Biosciences price target lowered to $36 from $43 at Baird | $36.00 |
| Jun 24, 2026 | Roth Capital | Castle Biosciences initiated with a Buy at Roth Capital | $40.00 |
| May 29, 2026 | KeyBanc | Castle Biosciences price target lowered to $35 from $50 at KeyBanc | $35.00 |
| Apr 20, 2026 | Canaccord Genuity | Castle Biosciences price target lowered to $40 from $50 at Canaccord | $40.00 |
| Jan 29, 2026 | KeyBanc | Castle Biosciences price target raised to $50 from $36 at KeyBanc | $50.00 |
| Jan 26, 2026 | Guggenheim | Castle Biosciences price target raised to $47 from $43 at Guggenheim | $47.00 |
| Jan 12, 2026 | Lake Street | Castle Biosciences price target raised to $52 from $35 at Lake Street | $52.00 |
| Jan 5, 2026 | Guggenheim | Castle Biosciences price target raised to $43 from $30 at Guggenheim | $43.00 |
| Dec 22, 2025 | Canaccord Genuity | Castle Biosciences price target raised to $50 from $37 at Canaccord | $50.00 |
| Dec 12, 2025 | BTIG | Castle Biosciences price target raised to $50 from $38 at BTIG | $50.00 |
| Mar 28, 2025 | Guggenheim | Castle Biosciences price target lowered to $30 from $37 at Guggenheim | $30.00 |
| Feb 28, 2025 | Robert W. Baird | Castle Biosciences price target raised to $37 from $36 at Baird | $37.00 |
| Nov 5, 2024 | Robert W. Baird | Castle Biosciences (CSTL) PT Raised to $39 at Baird | $39.00 |
| Nov 5, 2024 | BTIG | Castle Biosciences (CSTL) PT Raised to $45 at BTIG | $45.00 |
- 6 firms rate CSTL: 6 buy, 0 hold, 0 sell.
- The average price target is $38.75 from 4 analysts, from $35.00 to $44.00.
Updated 2026-11-02 17:51 UTC